Atomoxetine is NOT Recommended for Binge Eating Disorder
Atomoxetine is not an appropriate treatment for binge-eating disorder according to current clinical guidelines. The 2023 American Psychiatric Association guidelines specifically recommend either antidepressants or lisdexamfetamine as medication options for BED—atomoxetine is notably absent from these recommendations 1.
Guideline-Based Treatment Algorithm for BED
First-Line Treatment
- Eating disorder-focused cognitive-behavioral therapy (CBT) or interpersonal therapy (individual or group format) is the primary recommendation 1
Medication Considerations (Second-Line)
When medication is appropriate—specifically for patients who:
- Prefer medication treatment, OR
- Have not responded to psychotherapy alone after adequate trial
The APA suggests (2C rating) using:
- Antidepressant medication (typically SSRIs like fluoxetine), OR
- Lisdexamfetamine (the only FDA-approved medication for BED) 1
Why Atomoxetine Is Not Recommended
FDA Labeling
The atomoxetine FDA label clearly states it is approved only for ADHD, not for eating disorders 2. The label explicitly notes: "Atomoxetine hydrochloride is approved for ADHD in pediatric and adult patients. Atomoxetine hydrochloride is not approved for major depressive disorder" 2—and by extension, not for BED.
Limited Evidence Base
While one small randomized controlled trial from 2007 (N=40) showed atomoxetine reduced binge-eating episodes compared to placebo 3, this single study has not translated into guideline recommendations or FDA approval. The evidence is insufficient to support routine clinical use.
Safety Concerns
Atomoxetine carries significant warnings that are particularly problematic in eating disorder populations:
- Suicidal ideation risk in children and adolescents (black box warning) 2
- Common adverse effects include decreased appetite, nausea, constipation, and weight loss 2—which could be harmful in patients with eating disorders
- Sexual dysfunction occurs in 4-21% of patients 2
Clinical Pitfalls to Avoid
Do not use atomoxetine off-label for BED simply because:
- It's a norepinephrine reuptake inhibitor (like some antidepressants)
- One small study showed benefit
- The patient has comorbid ADHD (treat ADHD separately with appropriate agents)
If the patient has both BED and ADHD:
- Lisdexamfetamine is FDA-approved for both conditions and would be the logical choice 4, 5
- This addresses both disorders with a single, evidence-based medication
Bottom Line
Stick to guideline-recommended treatments: CBT/interpersonal therapy first, then consider antidepressants or lisdexamfetamine if medication is needed 1. Atomoxetine lacks the evidence base, guideline support, and FDA approval necessary for BED treatment, despite one positive preliminary study 3.